HGENQ — Humanigen Share Price
0.000.00%
Last trade - 00:00- $0.00m
- -$3.10m
- $2.51m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -3061.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.31 | 3.6 | 2.51 | 0.2 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The Company has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.
Directors
- Cameron Durrant CHM (60)
- Timothy Morris CFO (59)
- Ken Trbovich SVP
- Dale Chappell CSO (50)
- Edward Jordan OTH (53)
- Ronald Barliant IND (75)
- Rainer Boehm IND (60)
- Cheryl Buxton IND (61)
- John Hohneker IND (61)
- Y. Kevin Xie IND
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- September 19th, 2001
- Public Since
- January 30th, 2013
- No. of Shareholders
- 31
- No. of Employees
- 6
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 119,080,135
- Address
- 830 MORRIS TURNPIKE, 4TH FLOOR, SHORT HILLS, 07078
- Web
- https://www.humanigen.com/
- Phone
- +1 9732003100
- Auditors
- Horne LLP
Upcoming Events for HGENQ
Q4 2023 Humanigen Inc Earnings Release
Similar to HGENQ
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Humanigen share price?
As of Today at 21:12 UTC, shares in Humanigen are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Humanigen share price performed this year?
Shares in Humanigen last closed at $0.00 and the price had moved by -99.87% over the past 365 days. In terms of relative price strength the Humanigen share price has underperformed the S&P500 Index by -99.89% over the past year.
What are the analyst and broker recommendations for Humanigen?
The overall consensus recommendation for Humanigen is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Humanigen dividend yield?
Humanigen does not currently pay a dividend.
Does Humanigen pay a dividend?
Humanigen does not currently pay a dividend.
When does Humanigen next pay dividends?
Humanigen does not currently pay a dividend.
How do I buy Humanigen shares?
To buy shares in Humanigen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Humanigen?
As of the previous close price of $0.00, shares in Humanigen had a market capitalisation of $0.02m.
Where are Humanigen shares listed?
Here are the trading details for Humanigen:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: HGENQ
What kind of share is Humanigen?
Based on an overall assessment of its quality, value and momentum Humanigen is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Humanigen share price forecast for 2024?
The analyst consensus target price for shares in Humanigen is $0.15. That is 74900% above the last closing price of $0.00.
Analysts covering Humanigen currently have a consensus Earnings Per Share (EPS) forecast of -$0.15 for the next financial year.
What is the trend in the Humanigen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Humanigen. Over the past six months, its share price has underperformed the S&P500 Index by -79.88%.
As of the last closing price of $0.00, shares in Humanigen were trading -94.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Humanigen PE Ratio?
The Humanigen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Humanigen?
Humanigen's management team is headed by:
- Cameron Durrant - CHM
- Timothy Morris - CFO
- Ken Trbovich - SVP
- Dale Chappell - CSO
- Edward Jordan - OTH
- Ronald Barliant - IND
- Rainer Boehm - IND
- Cheryl Buxton - IND
- John Hohneker - IND
- Y. Kevin Xie - IND